Therapeutic flag Cosmetic cross-reference

Camphor

CAS 76-22-2

Camphor (CAS 76-22-2) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 24 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Camphor

CAS Number

76-22-2

UNII

5TJD82A1ET

InChIKey

DSSYKIVIOFKYAU-UHFFFAOYSA-N

ChEMBL ID

CHEMBL15768

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

CAMPHOR (SYNTHETIC)

natural producttherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL15768 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	14214.385714285712 nM	19	-
-	MIC	900 uL/ml	5	-
-	AC50	4980.2 nM	3	-
-	EC50	50 microg/cm2	2	-
-	Ki	50000 nM	1	-
-	MIC	200 ug.mL-1	1	-
Acetylcholinesterase Enzyme	Ki	4.3	-	Electrophorus electricus
Transient receptor potential cation channel subfamily A member 1 Ion channel	IC50	4.2	-	Mus musculus

SOURCE DrugCentral 24 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Methaemoglobinaemia	114	495.101	10027496
Urticaria thermal	11	51.664	10061399
Administration site erythema	10	39.207	10074796
Accidental exposure to product by child	13	37.677	10073318
Nail bed tenderness	8	35.171	10049268
Drug hypersensitivity	94	34.1	10013700
Cyanosis	23	30.336	10011703
Pigmentation disorder	14	29.49	10062080
Hypercholesterolaemia	21	24.908	10020603
Pruritus	96	23.034	10037087
Vulvovaginal swelling	6	22.934	10071211
Scratch	13	22.77	10039737
Haemolysis	15	22.308	10018910
Autonomic neuropathy	8	21.673	10061666
Vitamin B12 deficiency	12	21.042	10047609
Dizziness postural	13	19.372	10013578
Secretion discharge	14	17.967	10053459
Anxiety disorder	9	17.423	10057666
Fibromyalgia	28	16.107	10048439
Osteoarthritis	33	15.93	10031161
Skin plaque	11	15.253	10067723
Cellulitis	34	14.357	10007882
Dermatitis atopic	11	14.203	10012438
Nervousness	18	14.107	10029216

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
TRPA1 Trpa1	Antagonist	4.2 pIC50	16829128
TRPV1 TRPV1	Activator	-	-
TRPV3 Trpv3	Full agonist	2.0 pEC50	15746429

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
CAMPHOR (SYNTHETIC)	1371994	SU	MTHSPL
Camphor (Synthetic)	1371994	SU	MTHSPL
Camphor (synthetic)	1371994	SU	MTHSPL
camphor (synthetic)	1371994	SU	MTHSPL
camphor	1952	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Camphor used for in pharmaceutical contexts?

Camphor (CAS 76-22-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Camphor?

Camphor has 24 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Methaemoglobinaemia, Urticaria thermal, Administration site erythema, Accidental exposure to product by child, Nail bed tenderness. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Camphor also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Camphor with EU status "restricted".

What clinical phase is Camphor in?

Camphor is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Camphor?

Camphor has 8 bioactivity rows in this page query. Rendered target entries include Acetylcholinesterase, Transient receptor potential cation channel subfamily A member 1.